Nicotinamide riboside (NR) is a NAD+ precursor and vitamin B3 analog, branded primarily as Niagen® (ChromaDex). It competes with NMN as a NAD+ restoration strategy. Our research shows NR has MORE completed human clinical trials than NMN (as of 2026), including demonstration that 1,000mg/day raises NAD+ by 60% in overweight adults. However, the functional health outcomes have been disappointing: the largest NR trial (NIRI, 2021) found NO improvement in insulin sensitivity, body composition, or energy in overweight adults despite robust NAD+ elevation. This is the key NR dilemma: it reliably raises NAD+ in the blood, but translating that to health benefits in humans remains unproven.
NR enters cells via equilibrative nucleoside transporters (ENTs), then is phosphorylated by NR kinase (NRK1/2) to NMN, which is then adenylated by NMNAT to produce NAD+. This is one more step than NMN (which skips the NRK phosphorylation). The debate: NMN proponents argue NMN is "one step closer" to NAD+; NR proponents argue NR has better oral bioavailability and more clinical data. In practice, both reliably raise NAD+ in human blood. The gap: raising blood NAD+ does not automatically translate to tissue NAD+ or functional health benefits — which explains why the NIRI trial showed NAD+ up but no metabolic improvement.
No critical interactions identified.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.